Jiangsu Yahong Meditech Co Ltd

Action · CNE100005XW0 (XSHG)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur Jiangsu Yahong Meditech Co Ltd

Pas de cours

Cours de clôture XSHG 29.04.2026: 12,88 CNY

29.04.2026 03:16

Cours actuels de Jiangsu Yahong Meditech Co Ltd

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
SSE	688176.SS	CNY	29.04.2026 03:16	12,88 CNY	0,15 CNY +1,18 %

Flottant et Liquidité des Actions

Flottant Libre 99,99 %

Actions en Flottant 562,45 M

Actions en Circulation 562,5 M

Profil de l'entreprise pour Jiangsu Yahong Meditech Co Ltd Action

Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-1401 to treat moderately to severely active ulcerative colitis; and ASN-1733 to treat acinetobacter baumannii infection. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.